Impact of Catheter Ablation on ABC Risk Scores
Launched by HANNOVER MEDICAL SCHOOL · Nov 22, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effects of a procedure called catheter ablation on patients with certain heart rhythm problems, specifically atrial fibrillation and atrial flutter. The goal is to see how this procedure affects two specific risk scores related to stroke and bleeding, known as the ABC scores. This trial is looking for adults aged 18 and older who are experiencing symptoms from these heart conditions and are scheduled for their first catheter ablation. Participants will need to provide informed consent to join the study.
Once enrolled, participants will have blood samples taken at different times: before the procedure and again at 3, 6, and 12 months afterward. They will also be monitored closely for any possible recurrence of their heart rhythm issues using various devices, including an implanted monitor and possibly a smartwatch or smartphone. Through this trial, researchers hope to learn more about how effective catheter ablation is in reducing the risk of stroke and bleeding, as well as which monitoring methods work best after the procedure.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Symptomatic atrial tachyarrhythmias (atrial fibrillation, atrial flutter)
- • Planned for 1st right or left atrial ablation
- • Informed consent
- • at least 18 years
- Exclusion Criteria:
- • Previous left or right atrial ablation
- • Ineligibility for catheter ablation
- • History of TIA / stroke
- • \< 18 years
- • LA thrombus formation or history of thrombus formation
About Hannover Medical School
Hannover Medical School (Medizinische Hochschule Hannover, MHH) is a leading academic medical institution in Germany, renowned for its commitment to innovative research and high-quality clinical care. Established in 1965, MHH specializes in a wide range of medical disciplines, with a strong focus on transplantation medicine, regenerative medicine, and personalized healthcare. The institution actively participates in clinical trials to advance medical knowledge and develop cutting-edge therapies, leveraging its state-of-the-art facilities and collaborative environment. With a dedicated team of researchers, clinicians, and support staff, Hannover Medical School aims to translate scientific findings into practical applications that improve patient outcomes and enhance the overall quality of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hanover, Lower Saxony, Germany
Patients applied
Trial Officials
David Duncker, Prof. Dr.
Principal Investigator
Hannover Medical School, Carl-Neuberg Str. 1, 30625 Hannover
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials